PhaseBio Pharmaceuticals SG&A Expenses

SG&A Expenses of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending September 29, 2021 was $3.72 Million (a 7.93% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 13.64%
  • Annual SG&A Expenses for 2020 was $12.6 Million (a 14.24% increase from previous year)
  • Annual SG&A Expenses for 2019 was $11 Million (a 131.73% increase from previous year)
  • Annual SG&A Expenses for 2018 was $4.75 Million (a 112.9% increase from previous year)
  • Twelve month SG&A Expenses ending September 29, 2021 was $13.3 Million (a 5.51% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses increased by 4.63% year-over-year
Trailing SG&A Expenses for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$13.3 Million $12.6 Million $12.4 Million $12.7 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of PhaseBio Pharmaceuticals

Most recent SG&A Expensesof PHAS including historical data for past 10 years.

Interactive Chart of SG&A Expenses of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $3.72 $3.44 $2.85
2020 $3.27 $3.02 $3.24 $3.16 $12.58
2019 $3.66 $2.8 $2.4 $2.32 $11.01
2018 $2.24 $1.06 $0.92 $0.64 $4.75
2017 $0.57 $2.23
2016 $2.03

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.